Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Shares Outstanding (Weighted Average): 2012-2025

Historic Shares Outstanding (Weighted Average) for Adma Biologics (ADMA) over the last 10 years, with Sep 2025 value amounting to $238.6 million.

  • Adma Biologics' Shares Outstanding (Weighted Average) rose 2.38% to $238.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $238.6 million, marking a year-over-year increase of 2.38%. This contributed to the annual value of $236.4 million for FY2024, which is 4.61% up from last year.
  • Latest data reveals that Adma Biologics reported Shares Outstanding (Weighted Average) of $238.6 million as of Q3 2025, which was down 0.04% from $238.7 million recorded in Q2 2025.
  • Adma Biologics' 5-year Shares Outstanding (Weighted Average) high stood at $238.7 million for Q2 2025, and its period low was $121.3 million during Q1 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $231.8 million (2024), whereas its average is $230.9 million.
  • Data for Adma Biologics' Shares Outstanding (Weighted Average) shows a peak YoY skyrocketed of 107.11% (in 2021) over the last 5 years.
  • Adma Biologics' Shares Outstanding (Weighted Average) (Quarterly) stood at $195.8 million in 2021, then grew by 0.49% to $196.8 million in 2022, then climbed by 14.83% to $226.0 million in 2023, then climbed by 4.61% to $236.4 million in 2024, then grew by 2.38% to $238.6 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $238.6 million in Q3 2025, compared to $238.7 million in Q2 2025 and $237.6 million in Q1 2025.